Project Grant R56EY035219

Award Date 9/1/23
Completion Date 8/31/24
Dollars Obligated $498K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Eye Institute
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Farmington, CT 06032, USA
Similar Awards
This Project Grant award by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $583,250 to The Schepens Eye Research Institute, Inc. to identify the mechanisms underlying ocular toxicity caused by nitrogen mustard exposure and evaluate specialized lipid mediators as potential medical countermeasures. The key objectives are to: 1) Determine how nitrogen mustard alters the function of conjunctival goblet cells and if...
This $589,071.00 Project Grant awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) supports a research effort to study the immune mechanisms underlying chronic eye damage caused by exposure to nitrogen mustard, a type of chemical warfare agent. The key objectives are to (I) determine how the initial corneal inflammatory response activates harmful T-helper 17 cells that drive the development of mustard gas...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $961,980 to the University of Illinois to investigate the role of cellular senescence in the progression of mustard gas keratopathy (MGK), a severe and debilitating corneal condition that can develop years after exposure to chemical warfare agents. The key objectives are to (1) examine how senescence and the senescence-associated...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $937,468 to Northwestern University to conduct research on the pathological mechanisms of sulfur mustard gas keratopathy (MGK) in the cornea. The key objective is to investigate how autophagy, a cellular process, can play a detrimental role in MGK development and progression. The research team will explore how mustard gas...
This Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will provide $482,242 to The Medical College of Wisconsin, Inc. to conduct research on the mechanisms of mustard gas toxicity in the retina using a minipig model. The project aims to characterize the in vivo clinical, structural, and functional changes in the retina of a minipig model exposed to mustard gas, and identify molecular targets involved in retinal degenerative...
The National Eye Institute (NEI) awarded a $1,426,622 Project Grant (CFDA 93.867 - Vision Research) to The Washington University in St. Louis to investigate the neural mechanisms underlying corneal injuries caused by ammonia exposure. The key goals of the 4-year project are to: 1) characterize the extent of corneal nerve damage and related ocular pain in mouse models of ammonia-induced corneal injury, 2) delineate the activating mechanisms of corneal sensory nerves by ammonia, and 3) evaluate...
This Project Grant award, in the amount of $753,189, was provided by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867). The project will investigate the roles of basal epithelial cells in the central cornea, limbus, and conjunctiva in maintaining a healthy corneal epithelium and supporting wound healing. The research aims to identify novel therapeutic targets for the treatment of severe corneal epithelial defects, which can lead to blindness. The...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) supports research to examine the role of monocytes and neutrophils in fungal keratitis, a leading cause of corneal blindness and vision loss. The $1,083,078 award to the University of California, Irvine will fund studies across 3 key aims: 1) Evaluate neutrophil activation and the impact of monocyte depletion on neutrophil pro-inflammatory and fungal killing activity using...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,477,500 Project Grant to The Schepens Eye Research Institute, Inc., a non-profit organization affiliated with Harvard Medical School and Massachusetts Eye and Ear. The 3-year grant, awarded on September 1, 2023, will fund research on "Topical Calcitonin Gene-Related Peptide for Corneal Injury Prevention and Regeneration." The Schepens Eye Research Institute, which has...
This Project Grant award from the National Eye Institute (NEI), under CFDA Program 93.867 Vision Research, provides funding of $637,333 for research on the role of the optineurin (OPTN) gene in herpes simplex virus type-1 (HSV-1) eye infections. The research aims to investigate the molecular mechanisms by which OPTN regulates viral degradation, antigen presentation, and the impact on sensory nerve function in the cornea. The study will utilize in vitro and in vivo models, including wildtype...

This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support (CFDA 93.310) program provides $498,248 to the University of Connecticut Health Center (UCHC) to investigate the molecular mechanisms underlying corneal and retinal injury caused by exposure to chemical threat agents like nitrogen mustard. The key objectives are to: 1) Examine the role of the p53-PAD axis in driving corneal hypercitrullination, a pathological response, after nitrogen mustard exposure, using both in vivo and cell culture models; and 2) Characterize the temporal changes in the corneal and retinal "citrullinomes", or proteins modified by the enzyme peptidyl arginine deiminase (PAD), during the acute and chronic stages of injury. This research aims to unravel novel mechanisms and identify potential PAD enzyme targets for developing treatments to combat chemical-induced eye injury, an urgent medical need. The award period runs from September 1, 2023 to August 31, 2024.

Generated 7/16/24, 2:17 AM